| Issue |
Section |
Title |
File |
| Vol 22, No 2 (2020) |
Conference Proceedings |
Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic |
(Rus)
|
| Vol 22, No 2 (2020) |
Original Article |
High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy |
(Rus)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
The role of positron emission tomography in different types of malignant lymphomas: the results of 2020 |
(Rus)
|
| Vol 23, No 3 (2021) |
CLINICAL ONCOLOGY |
The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous? |
(Rus)
|
| Vol 24, No 1 (2022) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| Vol 25, No 4 (2023) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Evaluation of the effectiveness of hematopoietic blood stem cell mobilization using empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases: the experience of several centers in the Russian Federation. A retrospective study |
(Rus)
|
